Neptune Wellness Solutions Inc. (NEPT) and ObsEva SA (NASDAQ:OBSV) Contrasting side by side

Both Neptune Wellness Solutions Inc. (NASDAQ:NEPT) and ObsEva SA (NASDAQ:OBSV) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neptune Wellness Solutions Inc. N/A 0.00 N/A -0.07 0.00
ObsEva SA N/A 38140.21 76.72M -1.95 0.00

Demonstrates Neptune Wellness Solutions Inc. and ObsEva SA earnings per share, gross revenue and valuation.

Profitability

Table 2 shows Neptune Wellness Solutions Inc. and ObsEva SA’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Neptune Wellness Solutions Inc. 0.00% 0% 0%
ObsEva SA 0.00% -51.7% -46.9%

Insider and Institutional Ownership

Neptune Wellness Solutions Inc. and ObsEva SA has shares held by institutional investors as follows: 17.69% and 77.3%. Neptune Wellness Solutions Inc.’s share held by insiders are 23.43%. Comparatively, insiders own roughly 15.19% of ObsEva SA’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neptune Wellness Solutions Inc. -4.63% 3.86% 8.36% -14.63% 43.44% 37.8%
ObsEva SA 2.37% 2.29% -8.8% 0.39% -8.86% 2.37%

For the past year Neptune Wellness Solutions Inc. has stronger performance than ObsEva SA

Summary

Neptune Wellness Solutions Inc. beats ObsEva SA on 5 of the 7 factors.

Neptune Technologies & Bioressources Inc., a nutrition products company, focuses on providing nutrition solutions, including specialty ingredients and consumer brands. The company develops solutions available in various delivery forms. It also offers various specialty ingredients, including premium krill oil and other marine oils, as well as seed oils. The company sells its premium krill oil under the OCEANO3 brand directly to consumers through oceano3.com in Canada and the United States. In addition, Neptune Technologies & Bioressources Inc. is pursuing opportunities in the prescription drug markets, through its subsidiary, Acasti Pharma Inc., that focuses on the research, development, and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. The company was founded in 1925 and is headquartered in Laval, Canada.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.